Glactone Pharma is awarded financing from VINNOVA

Glactone Pharma has been awarded financing from the VINNOVA, Sweden’s Innovation Agency, for a new innovation project. The project is aimed at developing methods to design novel synthetic analogs…

Glactone Pharma is granted a European patent

The patent relates to novel synthetic analogs of the STAT3 inhibitor GPA500 with improved properties. Glactone Pharma is actively profiling novel small-molecule inhibitors of STAT3 for the treatment…

Glactone Pharma innovators publish new study showing that the STAT3 inhibitor galiellalactone reduces tumor growth and metastatic spread in an animal model of prostate cancer

Members of Glactone Pharma’s innovator group have published an article in the highly rated scientific journal European Urology: “The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer” is published in the journal European Urology, impact factor 13.938 (Eur Urol. 2015, doi:10.1016/j.eururo.2015.06.016).

Adenovir receives VINNOVA grant for second generation drug against contagious eye infection

​Adenovir develops drugs against the contagious eye disease EKC (epidemic keratoconjunctivitis), one of which is now being tested in phase II. VINNOVA, the Swedish Government Agency for Innovation Systems, has granted Adenovir SA Development AB SEK 500,000 for the pharmaceutical development of a second generation drug for the treatment of EKC.

Adenovir Pharma strengthens its board

​Adenovir Pharma has strengthened its board of directors with the addition of two new members with solid experience from the pharma industry, Karin Wingstrand and Mats Lidgard.
“It is very positive that we have managed to attract people like Karin and Mats to our board in the current phase, as we are preparing the company for an exit,” says Stefan Appelgren, chairman of the board, Adenovir.

American Society of Clinical Oncology (ASCO): Glactone Pharma demonstrates that new compound reduces immunosuppressive markers in prostate cancer cells

Glactone Pharma has generated new exciting data demonstrating that the STAT3 inhibitor GPA500 reduces immunosuppressive markers on treatment resistant prostate cancer cells and that activation of the oncogenic STAT3 pathway is a mechanism of treatment resistance. The results will be published as an abstract (J Clin Oncol 33, 2015 (suppl; abstr e16075)) at ASCO.

American Association for Cancer Research: Glactone Pharma to present data on the effect of new compound on anti-androgen resistant prostate cancer cells

Glactone Pharma will be presenting new exciting data at the annual meeting for AACR, on April 19, that demonstrate that the STAT3 inhibitor GPA500 suppresses the growth of prostate cancer cells resistant to second-generation anti-androgens. With GPA500 as a lead, Glactone Pharma has developed novel proprietary STAT3 inhibitors with improved drug like properties.

Share this page


Read more about our Protection of your personal data.